Skip to main content

Málstofa Lífvísindaseturs - Novel Peptide-Drug Conjugate Melphalan Flufenamide

Málstofa Lífvísindaseturs - Novel Peptide-Drug Conjugate Melphalan Flufenamide - á vefsíðu Háskóla Íslands
Hvenær 
3. september 2021 12:00 til 13:00
Hvar 

Læknagarður

stofa 201

Nánar 
Aðgangur ókeypis

Málstofa Lífvísindaseturs föstudaginn 3. september kl. 12:00 í Læknagarði stofu 201

Fyrirlesari: Dr. Ana Slipicevic, Oncopeptides AB, Sweden

Titill: Novel Peptide-Drug Conjugate Melphalan Flufenamide - A story of a successful industry-academia collaboration

Zoom link: https://eu01web.zoom.us/j/67319859829

StarfsferillAna Slipicevic Ph.D.  Translational research Director at Oncopeptides AB. She is responsible for the preclinical development of lead compounds and the implementation of translational research strategies in early clinical development. Before joining Oncopeptides AB, she was principal investigator in vivo pharmacology at Medivir AS as well as a researcher at the Department of Pathology, Oslo University Hospital, where she was leading a research group focusing on basic biology and therapy of melanoma.

Dr. Ana Slipicevic, Oncopeptides AB, Sweden

Málstofa Lífvísindaseturs - Novel Peptide-Drug Conjugate Melphalan Flufenamide